For patients with skin-brightening goals or specific pigmentation concerns, a range of evidence-supported topical and procedural treatments are available
Craik, D

(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)

The augmentation of iron intake, the decline in stored iron, and the alleviation of iron outflow can lead to increased Fe 2+ in the LIP in cells
The compound has never been the subject of a completed Phase III human clinical trial
So, injection is an extremely good treatment, but how often can you get a B12 shot, lets find out